紅太陽：與江蘇中邦製藥簽署75%乙醇消毒液產品全國獨家總代理框架協議
格隆匯2月9日丨紅太陽(000525.SZ)公佈，2020年2月9日，紅太陽與江蘇中邦製藥在南京市高淳區簽署“紅太陽牌75%乙醇消毒液”產品全國獨家總代理框架協議。
江蘇中邦製藥是紅太陽產業集團旗下歷經20年培育的一家集科研、生產製造、國內外市場為一體的以醫藥及醫藥中間體、醫藥新材料、衞生消毒劑、日用護理原料和保健食品生產製造、進出口、醫藥批發零售、物流倉儲全產業鏈的以醫藥為主業的高新技術實業公司。其產品涵蓋醫藥及醫藥中間體、醫藥新材料、衞生消毒劑、日用護理原料、保健食品等“一核四芯”高科技系列產品。近幾年來，江蘇中邦製藥利用自身的技術、團隊、市場和產業優勢，不僅幫助紅太陽實現了吡啶鹼產業鏈的“變廢為寶”和第五代新型殺蟲劑核心中間體的成功落地；而且針對我國心腦血管、消化道等高發慢性病和稀缺藥品凝血劑等應用開發，成功開發了中國領先和首創的拉唑類、沙坦類、沙班類等“三大”高科技產業鏈，市場覆蓋歐美、日本、韓國等幾十個國家和地區。
截至目前，江蘇中邦製藥擁有20多個國內急需和稀缺的醫藥原料及制劑藥在研在報在產在銷項目和產品；已申請專利88篇，擁有2個省級技術中心，1個省級外國專家工作室，3家市級技術中心，1個研究生工作站，1個高端人才團隊；已有2個產品獲得歐盟CEP證書，2個製劑產品正在進行臨牀審批。擁有符合國家GMP認證的醫藥原料藥生產線8條，生物提取物生產線4條，製劑生產線4條，定製加工生產線1條。已建成符合國家GSP要求的醫藥智能倉庫，總建築面積高達15,000㎡，並已成為長三角地區為數不多的符合第三方物流資格標準的國內先進藥品智能倉儲物流中心，輻射範圍覆蓋長三角及華東地區。
面對舉國上下抗擊新型冠狀病毒肺炎疫情的關鍵時刻，江蘇中邦製藥主動擔責，充分利用和發揮自身資源優勢，主動投身於疫情防控戰，通過整合內外部資源和周密部署，快速建成年產10萬噸75%乙醇消毒液生產線首期項目，而且還順利取得了“紅太陽牌75%乙醇消毒液”產品生產企業衞生許可證，並開始投入大規模生產，同時備足了未來三個月的原輔材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
